197 related articles for article (PubMed ID: 27471002)
1. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
Dousset C; Maïga S; Gomez-Bougie P; Le Coq J; Touzeau C; Moreau P; Le Gouill S; Chiron D; Pellat-Deceunynck C; Moreau-Aubry A; Amiot M
Br J Haematol; 2017 Nov; 179(4):684-688. PubMed ID: 27471002
[No Abstract] [Full Text] [Related]
2. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
3. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
[No Abstract] [Full Text] [Related]
4. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease.
Blombery P
Leuk Lymphoma; 2020 Feb; 61(2):257-262. PubMed ID: 31533509
[TBL] [Abstract][Full Text] [Related]
5. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
[TBL] [Abstract][Full Text] [Related]
6. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
[No Abstract] [Full Text] [Related]
7. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
8. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
10. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
Zou HS; Yi SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
[No Abstract] [Full Text] [Related]
11. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
12. Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation.
Leung N; Dingli D
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e488-e491. PubMed ID: 32466980
[No Abstract] [Full Text] [Related]
13. Targeting epigenetic mechanisms to overcome venetoclax resistance.
Prado G; Kaestner CL; Licht JD; Bennett RL
Biochim Biophys Acta Mol Cell Res; 2021 Jul; 1868(8):119047. PubMed ID: 33945824
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
[No Abstract] [Full Text] [Related]
15. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
16. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
17. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Place AE; Goldsmith K; Bourquin JP; Loh ML; Gore L; Morgenstern DA; Sanzgiri Y; Hoffman D; Zhou Y; Ross JA; Prine B; Shebley M; McNamee M; Farazi T; Kim SY; Verdugo M; Lash-Fleming L; Zwaan CM; Vormoor J
Future Oncol; 2018 Sep; 14(21):2115-2129. PubMed ID: 29595064
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.
Nwosu GO; Ross DM; Powell JA; Pitson SM
Cell Death Dis; 2024 Jun; 15(6):413. PubMed ID: 38866760
[TBL] [Abstract][Full Text] [Related]
19. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
20. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
